Celularity Stock Price, News & Analysis

Celularity Inc. (NASDAQ: CELU) is a regenerative and aging-related cellular medicine company in the pharmaceutical preparation manufacturing industry. According to the company’s public disclosures, Celularity develops, manufactures, and commercializes advanced biomaterial products and allogeneic and autologous cell therapies, all derived from the postpartum placenta. The company states that by harnessing the placenta’s unique biology and ready availability, it aims to create therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies that target fundamental aging mechanisms such as cellular senescence, age-related chronic inflammation, and tissue degeneration.

Business focus and placental-derived platform

Celularity consistently describes itself as a regenerative and cellular medicine company focused on age-related and degenerative diseases. Its platform centers on placental-derived technologies, including advanced biomaterial products and cryopreserved or other allogeneic cell therapies sourced from the postpartum placenta. The company highlights that these products and investigational therapies are aligned with use cases in wound care, orthopedics, pain management, and broader longevity and performance-related applications, where it sees substantial unmet medical need.

In earlier descriptions, Celularity has characterized itself as a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies, including genetically modified and unmodified natural killer (NK) cells, engineered T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It has also indicated that it evaluates its operations across business segments such as cell therapy, degenerative disease, and biobanking, with a significant contribution historically from biobanking activities.

Commercial advanced biomaterial products

Beyond its cell therapy pipeline, Celularity reports that it manufactures a range of commercial advanced biomaterial products derived from the postpartum placenta. Examples cited in company communications include Biovance and Biovance 3L, which are described as human amniotic membrane allograft products used in wound healing, as well as other placental-derived biomaterial offerings. The company notes that Biovance has been supported by a scalable manufacturing process since its commercial launch and that it has amassed real-world evidence from multiple studies and observational datasets regarding its use in chronic wound care.

Celularity has also referenced commercial products and sublicensed ophthalmic biologics such as Biovance, Biovance 3L, Interfyl, and CentaFlex within an ophthalmic portfolio. In eye care, these products are positioned within a broader strategy to expand the use of decellularized biologic solutions and placental-derived regenerative biologics through partnerships.

Cell therapy programs and PDA-002

The company’s disclosures describe a pipeline of human placenta-derived stem cell and mesenchymal stromal-like product candidates. One highlighted investigational therapy is PDA-002, a mesenchymal stromal-like cell therapy product derived from the postpartum placenta. Celularity has reported Phase 2 clinical trial results for PDA-002 in patients with diabetic foot ulcers, including those complicated by peripheral artery disease, describing data that demonstrate safety and efficacy in promoting durable wound closure and suggesting potential utility in ischemic wound care and other indications where microvascular disease is a factor.

Celularity has also indicated that PDA-002 qualifies as a stem cell therapy under a Florida statute authorizing certain physician-directed uses in wound care, orthopedics, and pain management. The company links this to its broader focus on regenerative wound care and age-related conditions, within a framework that includes both clinical trials and real-world clinical use where permitted by law.

Business structure and operating units

In its public announcements, Celularity has described an internal restructuring that formalized separate operating subsidiaries for its functional business units. These include an advanced biomaterial products commercial unit, a longevity-focused cellular therapeutics products unit, a contract development and manufacturing (CDMO) unit, and a neonatal and adult cell and tissue banking unit, as well as internal discovery and development and internal services units. The company explains that this structure is intended to reflect the fact that it operates multiple commercial businesses under one corporate umbrella, rather than a single discovery or development program.

Celularity has also noted that it maintains an FDA-registered, certified or accredited manufacturing and storage facility in Florham Park, New Jersey, where it produces commercial advanced biomaterial products and investigational cell therapy products, and maintains inventory of placenta-derived stem cell products for investigational and physician-directed use where permitted. The company emphasizes compliance with good manufacturing practice (GMP) and related standards in connection with these activities.

Strategic partnerships and market positioning

Celularity’s disclosures describe several strategic collaborations intended to expand the reach of its placental-derived technologies. For example, it has announced a partnership with Fountain Life, under which Celularity supplies stem cell therapy products for use in longevity and preventive health centers, particularly in Florida under the state’s stem cell law. It has also entered into an exclusive license and pricing arrangement with DefEYE, Inc., granting a sublicense to an ophthalmic biologics portfolio and serving as exclusive contract manufacturer for DefEYE’s ophthalmic biologic solutions.

In addition, Celularity has entered into an Asset Purchase Agreement and related License Agreement with Celeniv Pte. Ltd., under which it monetized certain intellectual property assets to retire senior secured debt while retaining exclusive licensed use of those assets for its cell therapy, advanced biomaterials, and biobanking businesses, along with an option to repurchase the assets over a defined period. The company presents this as part of a broader effort to improve its balance sheet and financial flexibility.

Financing, capital structure, and exchange listing

Celularity’s securities are listed on the Nasdaq Capital Market under the symbol CELU, and it has also listed warrants under a separate symbol. The company has reported multiple financing transactions, including senior secured term loans, secured convertible notes, warrants, and preferred stock offerings. For example, it has entered into a Securities Purchase Agreement for Series A Convertible Preferred Stock and accompanying warrants in a private placement, and it has completed financing transactions with an institutional investor involving a senior secured term loan, secured convertible notes, and warrants intended to support ongoing operations and strategic priorities.

The company has also described a major balance sheet restructuring that retired all of its senior secured debt and associated interest, funded in part through the monetization of intellectual property via the Celeniv transaction. In its filings, Celularity has discussed Nasdaq listing rule compliance related to timely filing of periodic reports and has reported regaining compliance after filing delayed Form 10-Q reports.

Corporate governance and stockholder matters

Celularity is incorporated in Delaware and files proxy statements and other reports with the U.S. Securities and Exchange Commission. In its definitive proxy materials, the company outlines matters submitted to stockholders, such as the election of directors, ratification of the independent registered public accounting firm, and amendments to its equity incentive plan to increase the number of shares reserved for awards. The proxy materials also describe the company’s capital structure, including its Class A common stock and authorized preferred stock, and provide information on corporate governance, executive compensation, and related party transactions.

Regulatory and geographic context

Celularity’s activities are shaped by U.S. federal and state regulatory frameworks, including FDA regulations for cell therapies and biologics and state-level laws such as the Florida statute governing certain stem cell therapies. The company highlights that its manufacturing facility is FDA-registered and certified or accredited by approved organizations, and that it complies with GMP and related quality standards. It has also emphasized the importance of Medicare coverage and reimbursement policies for its wound care products, noting developments in Centers for Medicare & Medicaid Services policies affecting skin substitute products.

Headquartered in Florham Park, New Jersey, Celularity positions its placenta-derived platform at the intersection of regenerative medicine, aging-related disease, wound care, and longevity-focused applications. Its disclosures present a combination of commercial biomaterial products, investigational cell therapies, biobanking services, and contract manufacturing capabilities, all connected by a common focus on the therapeutic potential of the postpartum placenta.